Publicaciones en las que colabora con Rafael Bárcena Marugán (21)

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2011

  1. Case report of splenic artery steal syndrome: Demonstration of portal hyperflow mechanism by anatomic variant of the splenic artery and correlation with doppler rates

    Transplantation Proceedings, Vol. 43, Núm. 6, pp. 2269-2271

  2. Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia

    Liver Transplantation, Vol. 17, Núm. 3, pp. 331-333

2010

  1. Partial splenic embolization and peg-IFN plus RBV in liver transplanted patients with hepatitis C recurrence: Safety, efficacy and long-term outcome

    Clinical Transplantation, Vol. 24, Núm. 3, pp. 366-374

  2. Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation

    Liver Transplantation

  3. Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage

    AIDS

2009

  1. False-positive results of aspergillus galactomannan antigenemia in liver transplant recipients

    Transplantation, Vol. 87, Núm. 2, pp. 256-260

2008

  1. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation

    AIDS

  2. Severe Sirolimus-Related Inflammatory State Anemia in an HIV+ Liver Transplant Patient With Calcineurin Inhibitor Renal Insufficiency: A Case Report

    Transplantation Proceedings, Vol. 40, Núm. 10, pp. 3810-3812

2006

  1. Improved graft function in liver-transplanted patients after partial splenic embolization: Reversal of splenic artery steal syndrome?

    Clinical Transplantation, Vol. 20, Núm. 4, pp. 517-523

2005

  1. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: An intent to find the optimal cut-off value

    Journal of Clinical Virology, Vol. 33, Núm. 2, pp. 138-144

  2. HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-α-2b/ribavirin

    Journal of Hepatology, Vol. 43, Núm. 5, pp. 783-790

  3. Is liver transplantation advisable for isoniazid fulminant hepatitis in active extrapulmonary tuberculosis?

    American Journal of Transplantation, Vol. 5, Núm. 11, pp. 2796-2798

  4. Liver transplantation in HIV-infected recipients

    Liver Transplantation, Vol. 11, Núm. 1, pp. 76-81

2004

  1. Trasplante hepático en patientes con infección por el VIH: Una realidad en el año 2004

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 22, Núm. 9, pp. 529-538

2003

  1. Analysis of hepatitis C viral quasispecies in liver transplantation

    Transplantation Proceedings

  2. Liver transplantation in a patient coinfected with human immunodeficiency virus and hepatitis C virus

    Transplantation Proceedings

  3. Prevention of invasive fungal infections in liver transplant recipients: The role of prophylaxis with lipid formulations of amphotericin B in high-risk patients

    Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 5, pp. 813-819

2002

  1. Prophylaxis with oral fluconazole and an oral solution of amphotericin B in liver transplant patients

    Transplantation Proceedings, Vol. 34, Núm. 1, pp. 80-81

2001

  1. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients

    Transplantation, Vol. 71, Núm. 1, pp. 145-149